Amplify Cybersecurity ETF vs Ionis Pharmaceuticals Inc. Common Stock — how do they compare? Amplify Cybersecurity ETF trades at $122 (market cap $3.56B), while Ionis Pharmaceuticals Inc. Common Stock trades at $42.5 (market cap $7.04B). The key difference: Ionis Pharmaceuticals Inc. Common Stock is the larger of the two by market cap, and Amplify Cybersecurity ETF is trading nearer its 52-week high, Ionis Pharmaceuticals Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Amplify Cybersecurity ETF for 27 Days and Ionis Pharmaceuticals Inc. Common Stock for 0 Days on average.
| HACK | IONS | |
|---|---|---|
Market Cap | $3.56B | $7.04B |
Volume | 331,197 | 2,977,440 |
Sector | Sector/Thematic | Health |
52-Week High | $130.76 | $86.50 |
52-Week Low | $70.69 | $42.38 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | — | $6.60B |
Signals from Pluang's Aura AI — not financial advice
HACK trades at $127.09, down 0.12% on the day, but maintains a bullish technical stance with moving averages signaling strength and momentum indicators like ADX showing strong trend confirmation. The ETF recently hit a 52-week high, driven by AI safety concerns and rising cybersecurity demand, though short interest has surged significantly, indicating mixed sentiment. Financial ratios are not applicable as this is an ETF tracking a basket of cybersecurity stocks.
The outlook for HACK is supported by structural growth in cybersecurity spending, particularly from AI-driven threats, but faces risks from elevated short interest and potential sector rotation. Upside depends on continued sector outperformance, while downside risks include profit-taking after strong gains and broader tech volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →